AstraZeneca (HAM:ZEG) Cyclically Adjusted FCF per Share: €2.88 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:ZEG AstraZeneca PLC HAM:ZEG
88 GF Score
Price €148.25
GF Value €157.71
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is AstraZeneca Cyclically Adjusted FCF per Share?

AstraZeneca HAM:ZEG -0.34% 88 Cyclically Adjusted FCF per Share is €2.88 as of Mar. 2026. GuruFocus rates HAM:ZEG with a GF Score™ of 88/100 and a GF Value™ of €157.71 (Fairly Valued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

AstraZeneca's adjusted free cash flow per share for the three months ended in Mar. 2026 was €1.009. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €2.88 for the trailing ten years ended in Mar. 2026.

During the past 12 months, AstraZeneca's average Cyclically Adjusted FCF Growth Rate was 11.60% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 11.00% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 10.40% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was -2.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of AstraZeneca was 39.60% per year. The lowest was -15.00% per year. And the median was 5.20% per year.

As of today (2026-07-24), AstraZeneca's current stock price is €148.25. AstraZeneca's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €2.88. AstraZeneca's Cyclically Adjusted Price-to-FCF of today is 51.48.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 16.35. And the median was 50.86.


AstraZeneca  (HAM:ZEG) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

AstraZeneca's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=148.25/2.88
=51.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of AstraZeneca was 73.79. The lowest was 16.35. And the median was 50.86.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


AstraZeneca Cyclically Adjusted FCF per Share Related Terms


AstraZeneca Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for AstraZeneca's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AstraZeneca Cyclically Adjusted FCF per Share Chart

AstraZeneca Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.71 2.05 2.14 2.41 2.80

AstraZeneca Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.68 2.71 2.76 2.80 2.88

HAM:ZEG vs LLY, JNJ, ABBV: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - General subindustry, AstraZeneca's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AstraZeneca Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, AstraZeneca's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where AstraZeneca's Cyclically Adjusted Price-to-FCF falls into.


HAM:ZEG
88GF Score
AstraZeneca PLC HAM:ZEG
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AstraZeneca Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, AstraZeneca's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.009/140.8000*140.8000
=1.009

Current CPI (Mar. 2026) = 140.8000.

AstraZeneca Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -0.577 101.000 -0.804
201609 0.313 101.500 0.434
201612 0.988 102.200 1.361
201703 -0.219 102.700 -0.300
201706 -0.057 103.500 -0.078
201709 1.252 104.300 1.690
201712 0.297 105.000 0.398
201803 -0.303 105.100 -0.406
201806 -0.199 105.900 -0.265
201809 0.135 106.600 0.178
201812 1.259 107.100 1.655
201903 -0.801 107.000 -1.054
201906 -0.065 107.900 -0.085
201909 0.527 108.400 0.685
201912 0.679 108.500 0.881
202003 -0.163 108.600 -0.211
202006 0.043 108.800 0.056
202009 0.723 109.200 0.932
202012 0.783 109.400 1.008
202103 0.933 109.700 1.198
202106 0.339 111.400 0.428
202109 0.602 112.400 0.754
202112 0.397 114.700 0.487
202203 1.669 116.500 2.017
202206 0.428 120.500 0.500
202209 1.178 122.300 1.356
202212 1.116 125.300 1.254
202303 0.996 126.800 1.106
202306 0.731 129.400 0.795
202309 1.342 130.100 1.452
202312 0.842 130.500 0.908
202403 0.520 131.600 0.556
202406 1.439 133.000 1.523
202409 1.168 133.500 1.232
202412 1.193 135.100 1.243
202503 1.626 136.100 1.682
202506 0.814 138.400 0.828
202509 1.860 138.900 1.885
202512 0.576 139.900 0.580
202603 1.009 140.800 1.009

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €2.88 mean?
AstraZeneca (HAM:ZEG) has a Cyclically Adjusted FCF per Share of €2.88 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AstraZeneca and its competitors.
Is AstraZeneca's Cyclically Adjusted FCF per Share too high?
AstraZeneca's current Cyclically Adjusted FCF per Share is €2.88. Overall, AstraZeneca has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AstraZeneca's Cyclically Adjusted FCF per Share compare to LLY and JNJ?
AstraZeneca's Cyclically Adjusted FCF per Share of €2.88 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on AstraZeneca and its competitors. AstraZeneca's current Cyclically Adjusted FCF per Share is €2.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AstraZeneca stock overvalued right now?
Based on GuruFocus' analysis, AstraZeneca (HAM:ZEG) is currently considered Fairly Valued. The stock's GF Value™ is €157.71, compared to a current price of €148.25 — trading 6% below its estimated fair value. The current Cyclically Adjusted FCF per Share is €2.88. AstraZeneca's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For AstraZeneca (HAM:ZEG), the current Cyclically Adjusted FCF per Share is €2.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AstraZeneca (HAM:ZEG) Overvalued in 2026?

Based on GuruFocus' analysis, AstraZeneca stock appears to be undervalued. The current stock price of €148.25 is trading 6% below its estimated GF Value™ of €157.71. GuruFocus considers AstraZeneca to be Fairly Valued.

Key valuation signals for HAM:ZEG:

  • Cyclically Adjusted FCF per Share: €2.88
  • GF Value™: €157.71 vs. price of €148.25 (6% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the HAM:ZEG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


AstraZeneca Business Description

Address 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, GBR, CB2 0AA
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.
88GF Score

Get the complete analysis for HAM:ZEG

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€148.25
Price
€157.71
GF Value